期刊名称：EXPERT OPINION ON INVESTIGATIONAL DRUGS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Expert Opinion on Investigational Drugs (ISSN 1354-3784) is a monthly peer-reviewed journal, evaluating developments in pharmaceutical research, from animal studies through to the launch of a new medicine.
Authors are encouraged to express their Expert Opinion of the status of the research under review, rather than simply reviewing the available data. Each issue of the journal also contains Editorials, Drug Evaluations, Clinical Trial Reports, Meeting Highlights and Paper Evaluations.
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, and many biotechnology companies. Expert Opinion on Investigational Drugs adopts a systematic approach to coverage, with each issue focusing on one of the major therapeutic areas. The major themes covered are as follows:
- Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis
- Anti-infective
- Endocrine & Metabolic
- Central & Peripheral Nervous Systems
- Cardiovascular & Renal
- Oncologic
Sources
Permission has been kindly granted by the publisher of the following information source for Ashley Publications to provide its authors with relevant source material for use solely in the preparation of their reviews for Expert Opinion on Investigational Drugs:
- Investigational Drugs database (?Current Drugs Ltd.)
Citations
Expert Opinion on Investigational Drugs is indexed by:
- Chemical Abstracts
- Current Contents?Life Sciences
- EMBASE/Excerpta Medica
- ISI Alerting Services
- Medline
- Science Citations Index-Expanded
Instructions to Authors
The Commissioning Editor, under the advice of the Editorial Board, solicits articles published in Expert Opinion on Investigational Drugs. However, suggestions for article topics (and potential authors) are welcome, subject to final approval by the Editors and Editorial Board. If you are interested in preparing an article, please contact the Commissioning Editor (korin@ashley-pub.com) with your proposal and an outline.
The following guidelines (PDF files) are provided to assist authors in the preparation of their manuscript.
Review
Clinical Trials Report
Editorial
Drug Evaluation
Expert Opinion EndNote Style
Editorial Board
The Senior Advisory Panel and Section Editorial Board are composed of Senior Scientists involved in drug research and development. The Senior Advisory Panel is responsible for the development of the journal, while the Section Editors are responsible for selecting authors and topics for review to ensure comprehensive coverage of subjects in each therapeutic area.
Pulmonary-Allergy
Cochran FR: GlaxoSmithKline, USA
Ferro M: RW Johnson Pharmaceutical Research Institute, USA
Foster M: AstraZeneca, UK
Garst ME: Allergan, USA
Handley D: Sepracor, USA
Morley J: Haldane Research, UK
Norris A: Admiral, Spain
Richards IM: Pharmacia Corp., USA
Roomans GM: Univ. Uppsala, Sweden
Sircar JC: Avanir Pharmaceuticals, USA
Warne P: Aventis, UK
Endocrine
Brandi ML: Univ. of Florence, Italy
Briggs M: Pharmacia Corp., USA
Colca J: Pharmacia Corp., USA
Dujovne C: Radiant Research
Fuller P: Prince Henry's Institute of Medical Research, Australia
Kowluru R: Kresge Eye Institute, USA
Proietto J: Univ. of Melbourne, Australia
Whitfield J: National Research Council, Canada
Senior Advisory Panel
Chairman: Fitzgerald JD: Materia Medica, UK
Abou-Gharbia M: Wyeth-Ayerst, USA
Baldwin JJ: Pharmacopeia, USA
Barry DW: Triangle Pharm., USA
Buckel P: Boehringer Mannheim, Germany
Duncan WAM: RW Johnson, USA
Evans C: Chiroscience, UK
Gillis S: Corixa, USA
Harrap K: Inst. Cancer Research, UK
Hoyer D: Novartis, Switzerland
Humphrey PPA: GlaxoSmithKline, UK
Krogsgaard Thomsen M: Novo, Denmark
Moncada S: The Cruciform Project, UK
Morich F-J: Bayer, Germany
Okazaki H: Takeda, Japan
Paioni R: Novartis, Switzerland
Poste G: Health Technology Networks, USA
Ringrose PS: Bristol-Myers Squibb, USA
Ross BC: GlaxoSmithKline, UK
Setoyama O: Chugai, Japan
Sugino Y: Takeda, Japan
Timmermanns P: DuPont, USA
Weston A: Univ. Manchester, UK
Anti-infectives
Barrett JF: Bristol-Myers Squibb, USA
Blondeau J: Univ. of Saskatchewan, Canada
Bryskier A: Aventis, France
Buckheit R: Southern Research Institute, USA
Chopra I: Antimicrobial Research Centre, UK
Clerici M: Polo LITA, Italy
Georgopapadakou N: NewBiotics, USA
Neamati N: Univ. Southern California, USA
Ryder N: Novartis, Australia
Turik M: Eli Lilly, USA
Cardiovascular & Renal
Barton M: Univ. Hospital Zurich, Switzerland
Danser AHJ: Erasmus Universiteit Rotterdam, The Netherlands
Gristwood RW: Arachnova Ltd, UK
Herbert J-M: Sanofi-Synthelabo, France
Holvoet P: Univ. of Leuven, Belgium
Julian DG: CTR Advisor, UK
Nicholson CD: Organon International, The Netherlands
Primeau JL: Wyeth-Ayerst Research, USA
Ruffolo RR: GlaxoSmithKline, USA
Siegl P: Merck & Co., USA
Winkelmann BR: Heart Center Ludwigshafen, Germany
Woods M: GlaxoSmithKline, UK
Central & Peripheral Nervous Systemsm
Gurwitz D: Tel-Aviv Univ., Israel
Heydorn WE: Forest Lab., USA
Hill RG: Merck Sharpe & Dohme, UK
Kloog Y: Tel-Aviv Univ., Israel
McCall JM: Pharmacia Corp., USA
Nagase H: Univ. of Kansas, USA
Palacios JM: Laboratorios Almirall SA, Spain
Panetta JA: Eli Lilly, USA
Saxena P: Erasmus Universiteit Rotterdam, The Netherlands
Schachter S: Beth Israel Deaconess Medical Center, USA
Sramek J: California Clinical Trials, USA
Temple DL: Consulting Services, USA
Williams M: Abbott, USA
Oncologic
Bell, P Novartis (Sandoz) Research Institute, USA
Bramhall SR: Univ. of Birmingham, UK
Denny WA: Univ. of Auckland, New Zealand
Gibbs JB: Merck & Co., USA
Kelland L: CRC Centre for Cancer Therapeutics, UK
Koutsilieris M: University of Athens, Greece
Papavassiliou AG: Univ. of Patras, Greece
Sawyer TK: Ariad Pharmaceuticals, USA
Williams R: Prolifix Ltd, UK
Zhang WW: UroGen Corp., USA
|
